Glaxosmithkline Pharma

Motilal Oswal recommended Neutral rating on GlaxoSmithKline Pharma with a target price of Rs 1300 in its research report dated March 16, 2023.

Buy Britannia, GSK Pharma; sell HDIL, SAIL: Parag Doctor

Parag Doctor of Keynote Capital recommended buying Britannia Industries and Glaxosmithkline Pharma. However, he advised one can sell HDIL and SAIL.

Bull's Eye: Buy Britannia, Videocon; short HDIL, RComm

Sharmila Joshi of Peerless Securities advised buying Sterlite Industries with a target price of Rs 96.50. Meanwhile, Parag Doctor of Keynote Capital advised buying Britannia Industries with a stoploss at Rs 700 and for a target price of Rs 750.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained a neutral rating on GlaxoSmithKline Pharma in its February 20, 2013 research report. The research firm expects company's net sales to post a 13.0% CAGR to Rs 3,319cr and EPS to register a 4.1% CAGR to Rs 86.7 over CY2012–14.

Accumulate GSK Pharma; target of Rs 2104: Dolat Capital

Dolat Capital is bullish on GlaxoSmithKline Pharma and has recommended accumulate rating on the stock with a target of Rs 2104 in its November 21, 2012 research report.

How to trade pharma stocks ahead of Q4 earnings

Dolat Capital has come out with its report on pharma sector.

Buy GSK Pharma; target of Rs 2234: Motilal Oswal

Motilal Oswal is bullish on GlaxoSmithKline Pharma and has recommended buy rating on the stock with a target of Rs 2234 in its March 1, 2012 research report.

Sell GlaxoSmithKline Pharma; tgt of Rs 1880: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1880 in its March 1, 2012 research report.

GlaxoSmithKline Pharma Q4 net up 18% at Rs 136.74 cr

GlaxoSmithKline Pharmaceuticals' fourth quarter net profit rose 18% year-on-year to Rs 136.74 crore, helped by continued growth of specialty products and vaccines, and new product launches.

Buy JSW Steel, GlaxoSmithKline Pharma, says Sukhani

Buy JSW Steel and GlaxoSmithKline Pharma, says Sudarshan Sukhani, s2analytics.com.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma in its November 16, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma (Glaxo), in its August 10, 2011 research report.

Sell GSK Pharma; target of Rs 1809: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1809 in its May 9, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma, in its May 6, 2011 research report.

Hold GlaxoSmithKline Pharma; target of Rs 2161: Emkay

Emkay Global Financial Services has maintained hold rating on GlaxoSmithKline Pharma (GSK Pharma) with a target of Rs 2161 in its February 21, 2011 research report.

Angel Broking neutral on GlaxoSmithKline Pharma

Angel Broking has maintained neutral rating on GlaxoSmithKline Pharma (Glaxo), in its February 18, 2011 research report.

Sell GSK Pharma; target of Rs 1754: PINC Research

PINC Research is bearish on GlaxoSmithKline Pharma and has recommended sell rating on the stock with a target of Rs 1754 in its February 21, 2011 research report.

GSK Pharma Dec qtr PAT seen up 11% at Rs 114.9cr: Karvy

Karvy Stock Broking has come out with its earning estimates on pharma sector for the quarter ended December 2010. According to the research firm, GlaxoSmithkline Pharma December quarter sales are expected to go up by 13.1% at Rs 509 crore, Year-on-Year, (YoY) basis.